Breaking news: The Texas Longhorns just reached a $150 million trade agreement with….

Breaking news: The Texas Longhorns just reached a $150 million trade agreement with….

Dallas-based Taysha Gene Therapies is reeling in a $150 million lifeline from investors to advance clinical studies of its gene therapy medicines for rare neurological diseases.

The new funding, led by RA Capital Management, extends Taysha’s cash runway into late 2025 and provides a cushion to complete clinical trials on its gene therapy for Rett syndrome, a rare genetic disorder that occurs almost exclusively in girls and severely impairs their ability to speak, walk, eat and even breathe.

Be the first to comment

Leave a Reply

Your email address will not be published.


*